BIOCRYST PHARMACEUTICALS INC reported 2 exit or restructuring plans on Form 8-K under Item 2.05. Each fact below is the filing's own sentence, quoted and linked. No WARN notice under this company's name is on file in the states covered here.
SEC filings: exit or restructuring (Item 2.05)
BIOCRYST PHARMACEUTICALS INC (CIK 882796) reported 2 exit or restructuring plans to the SEC on Form 8-K under Item 2.05. The sentences below are quoted from the filings as written.
Form 8-K/A filed 2026-08-04
Locations
On June 29, 2026, the Company announced its plan to discontinue the Company's internal discovery programs and close its Discovery Center of Excellence facility in Birmingham, Alabama (the "Plan") as part of the Company's ongoing strategic evolution to strengthen its rare disease pipeline.
Expected charges
The Company now estimates that it will incur between $6.2 and $7.5 million in one-time expenses in connection with employee termination benefits and severance, of which approximately $5.3 to $6.6 million are expected to be cash expenditures.
Form 8-K filed 2026-06-29
Locations
On June 25, 2026, the Board of Directors of BioCryst Pharmaceuticals, Inc. (the "Company") approved a plan to discontinue the Company's internal discovery programs and close its Discovery Center of Excellence facility in Birmingham, Alabama (the "Plan").
Timing
The implementation of the Plan is expected to be substantially complete by the end of 2026.
Want the whole picture on BIOCRYST PHARMACEUTICALS INC?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on BIOCRYST PHARMACEUTICALS INC: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on BIOCRYST PHARMACEUTICALS INC covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Tools for this story
Each opens in a new tab, filled in for BIOCRYST PHARMACEUTICALS INC. With no account yet, you sign up free and land on the result.
Public companies must also report to the SEC, on Form 8-K under Item 2.05, when they commit to an exit or restructuring plan that will cost them material charges, which is how most large layoffs and closures by listed companies are disclosed. Those filings are national, so they cover companies in every state. Each sentence shown from one is quoted exactly and linked to the filing; where a filing does not state a figure, none is shown.
Where this comes from
Employers covered by the federal WARN Act, and by the stricter laws some states add, must give written notice before a mass layoff or a site closure. The state labor department publishes those notices. Every row here is one of them, taken from that state's own published file and linked to it, so each figure can be checked at the source.
A notice states the employer, the location, the number of employees affected, and when the layoff or closure takes effect. It does not state a reason, and neither does this page. Where a company also appears in SEC filings under the same name and in the same state, its recorded fundraising is shown alongside, as a matter of record rather than as an explanation. New Jersey publishes the month a notice was posted, not the day, so New Jersey notices show a month.
More on BioCryst Pharmaceuticals, Inc.
Related
- Amazon: 10 WARN notices, 5,502 employees, Aug 2026 layoff notice within 90 days (2026-08-31)
- Kaiser: 16 WARN notices, 147 employees, Sep 2026 layoff notice within 90 days (2026-09-21)
Cite this page
https://mentionfox.com/layoffs/biocryst-pharmaceuticals